What is Agilon Health Inc's earnings per share (EPS)?

Agilon Health Inc (AGL) reported diluted earnings per share of $-0.98 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Agilon Health Inc Financials

AGL

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Agilon Health Inc (AGL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AGL FY2025 2026-05-06

Rapid revenue scaling has not produced operating leverage, leaving a thin liquidity cushion despite minimal debt.

Between FY2022 and FY2025, revenue climbed from $2.4B to $5.9B without turning scale into operating leverage. Because operating margin worsened to -7.8% in FY2025 even as SG&A fell to $239M, the pressure looks embedded in the core economics of each revenue dollar rather than in corporate overhead alone.

The balance sheet has been thinned mainly by accumulated losses, not by borrowing: long-term debt is only $15.8M, but equity has been worn down to $127M. That erosion helps explain why the current ratio slid from 3.8x in FY2021 to 1.0x in FY2025, meaning short-term flexibility is now much tighter even though leverage remains modest.

Cash usage is meaningfully lighter than reported losses imply: FY2025 net loss was -$391M while operating cash flow was -$106M. With capital spending only $13M, this is a capital-light business where the central issue is the recurring gap between accounting profitability and sustainable cash generation, not heavy reinvestment demands.

Financial Health Signals

Financial Health Score 40/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Agilon Health Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Agilon Health Inc has an operating margin of -7.8%, meaning the company retains $-8 of operating profit per $100 of revenue. This results in a moderate score of 30/100, indicating healthy but not exceptional operating efficiency. This is down from -4.8% the prior year.

Growth

Agilon Health Inc's revenue declined 2.1% year-over-year, from $6.1B to $5.9B. This contraction results in a growth score of 79/100.

Leverage

Agilon Health Inc carries a low D/E ratio of 0.12, meaning only $0.12 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 79/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Agilon Health Inc's current ratio of 1.02 is below the typical benchmark, resulting in a score of 19/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

While Agilon Health Inc generated -$105.8M in operating cash flow, capex of $13.2M consumed most of it, leaving -$119.0M in free cash flow. This results in a low score of 24/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Agilon Health Inc generates a -308.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 11/100. This is down from -55.2% the prior year.

Altman Z-Score Grey Zone

2.32

Agilon Health Inc scores 2.32, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Agilon Health Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.27x

For every $1 of reported earnings, Agilon Health Inc generates $0.27 in operating cash flow (-$105.8M OCF vs -$391.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-69.8x

Agilon Health Inc earns $-69.8 in operating income for every $1 of interest expense (-$463.2M vs $6.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.9B

YoY-2.1%

5Y CAGR+37.2%

Agilon Health Inc generated $5.9B in revenue in fiscal year 2025. This represents a decrease of 2.1% from the prior year.

EBITDA

-$434.6M

YoY-62.4%

Agilon Health Inc's EBITDA was -$434.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 62.4% from the prior year.

Net Income

-$391.3M

YoY-50.4%

Agilon Health Inc reported -$391.3M in net income in fiscal year 2025. This represents a decrease of 50.4% from the prior year.

EPS (Diluted)

$-0.98

Agilon Health Inc earned $-0.98 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$119.0M

YoY-67.5%

Agilon Health Inc generated -$119.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 67.5% from the prior year.

Cash & Debt

$173.7M

YoY-7.7%

5Y CAGR+10.2%

Agilon Health Inc held $173.7M in cash against $15.8M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

17M

Agilon Health Inc had 17M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

-7.8%

YoY-3.0pp

5Y CAGR-3.2pp

Agilon Health Inc's operating margin was -7.8% in fiscal year 2025, reflecting core business profitability. This is down 3.0 percentage points from the prior year.

Net Margin

-6.6%

YoY-2.3pp

5Y CAGR-1.7pp

Agilon Health Inc's net profit margin was -6.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 2.3 percentage points from the prior year.

Return on Equity

-308.8%

YoY-253.5pp

Agilon Health Inc's ROE was -308.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 253.5 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

Agilon Health Inc spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$13.2M

YoY-0.1%

5Y CAGR+49.5%

Agilon Health Inc invested $13.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 0.1% from the prior year.

AGL Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$5.9B-2.1%	$6.1B+40.4%	$4.3B+80.7%	$2.4B+57.0%	$1.5B+24.9%	$1.2B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$238.5M-11.3%	$268.9M-5.9%	$285.8M+37.5%	$207.8M-51.4%	$427.5M+211.4%	$137.3M
Operating Income	-$463.2M-58.6%	-$292.1M-25.8%	-$232.1M-120.3%	-$105.4M+71.7%	-$372.2M-556.8%	-$56.7M
Interest Expense	$6.6M+7.5%	$6.2M-7.2%	$6.7M+48.5%	$4.5M-27.0%	$6.1M-24.4%	$8.1M
Income Tax	$1.3M-13.8%	$1.5M+83.4%	$791K-51.8%	$1.6M+85.1%	$886K+2.4%	$865K
Net Income	-$391.3M-50.4%	-$260.2M+0.9%	-$262.6M-146.4%	-$106.6M+73.8%	-$406.5M-576.9%	-$60.1M
EPS (Diluted)	$-0.98	$-0.61-27.1%	$-0.48-118.2%	$-0.22+78.6%	$-1.03-415.0%	$-0.20

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$1.4B-9.5%	$1.6B+9.3%	$1.4B+2.9%	$1.4B-9.0%	$1.5B+0.7%	$1.5B+4.9%	$1.5B-2.1%	$1.5B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$54.2M-9.8%	$60.1M+6.9%	$56.2M-0.1%	$56.3M-14.7%	$66.0M+10.4%	$59.8M-5.3%	$63.1M-9.3%	$69.6M
Operating Income	$4.0M+102.1%	-$193.8M-47.6%	-$131.3M-13.1%	-$116.0M-424.8%	-$22.1M+79.5%	-$108.1M+19.0%	-$133.5M-208.0%	-$43.3M
Interest Expense	$1.8M+5.5%	$1.7M-6.6%	$1.8M+16.9%	$1.6M+3.8%	$1.5M-3.7%	$1.6M-3.0%	$1.6M-4.4%	$1.7M
Income Tax	$28K-97.9%	$1.3M+500.0%	-$331K-633.9%	$62K-68.4%	$196K-88.8%	$1.8M+397.8%	-$590K-241.5%	$417K
Net Income	$48.9M+125.9%	-$188.9M-71.4%	-$110.2M-5.6%	-$104.4M-961.7%	$12.1M+111.4%	-$105.8M+10.1%	-$117.6M-283.3%	-$30.7M
EPS (Diluted)	$2.94	N/A	$-0.27-8.0%	$-0.25-134.2%	$0.73	N/A	$-0.29-314.3%	$-0.07

AGL Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.3B-26.7%	$1.7B-0.4%	$1.7B+2.6%	$1.7B+7.0%	$1.6B+255.4%	$446.4M
Current Assets	$1.1B-24.8%	$1.5B-1.5%	$1.5B+2.0%	$1.5B+6.1%	$1.4B+364.7%	$294.2M
Cash & Equivalents	$173.7M-7.7%	$188.2M+75.0%	$107.6M-76.9%	$465.3M-55.3%	$1.0B+873.9%	$106.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$0-100.0%	$24.1M0.0%	$24.1M+860.3%	$2.5M-94.0%	$41.5M0.0%	$41.5M
Total Liabilities	$1.1B-9.4%	$1.3B+17.0%	$1.1B+64.4%	$656.9M+32.8%	$494.7M-32.3%	$731.1M
Current Liabilities	$1.1B-6.6%	$1.2B+17.9%	$977.2M+82.6%	$535.1M+49.9%	$357.0M+33.8%	$266.8M
Long-Term Debt	$15.8M-54.9%	$34.9M+8.0%	$32.3M-16.0%	$38.5M-11.3%	$43.4M-32.9%	$64.7M
Total Equity	$126.7M-73.1%	$471.0M-28.8%	$661.8M-36.4%	$1.0B-4.6%	$1.1B+483.5%	-$284.7M
Retained Earnings	-$2.0B-24.7%	-$1.6B-19.6%	-$1.3B-24.7%	-$1.1B-11.1%	-$957.7M-73.7%	-$551.2M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$1.5B+18.4%	$1.3B-20.4%	$1.6B-6.8%	$1.7B-11.4%	$1.9B+11.5%	$1.7B-17.1%	$2.1B-3.3%	$2.2B
Current Assets	$1.3B+20.5%	$1.1B-18.0%	$1.3B-7.9%	$1.5B-12.0%	$1.7B+13.2%	$1.5B-19.5%	$1.8B-3.8%	$1.9B
Cash & Equivalents	$140.0M-19.4%	$173.7M+1.2%	$171.7M+0.2%	$171.4M+25.2%	$136.9M-27.2%	$188.2M+27.0%	$148.2M+35.3%	$109.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	$0-100.0%	$24.1M0.0%	$24.1M0.0%	$24.1M0.0%	$24.1M0.0%	$24.1M0.0%	$24.1M
Total Liabilities	$1.3B+15.6%	$1.1B-11.3%	$1.3B-1.1%	$1.3B-9.0%	$1.4B+13.4%	$1.3B-16.7%	$1.5B+2.0%	$1.5B
Current Liabilities	$1.3B+18.2%	$1.1B-13.2%	$1.2B-0.7%	$1.2B-9.1%	$1.4B+19.3%	$1.2B-18.2%	$1.4B+1.6%	$1.4B
Long-Term Debt	$15.3M-3.0%	$15.8M	$0	$0	$0-100.0%	$34.9M+0.1%	$34.9M+27.5%	$27.4M
Total Equity	$181.4M+43.2%	$126.7M-58.6%	$306.1M-25.2%	$408.9M-18.3%	$500.3M+6.2%	$471.0M-18.1%	$574.9M-15.0%	$676.6M
Retained Earnings	-$1.9B+2.5%	-$2.0B-10.6%	-$1.8B-6.6%	-$1.7B-6.6%	-$1.6B+0.8%	-$1.6B-7.1%	-$1.5B-8.6%	-$1.4B

AGL Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$105.8M-83.1%	-$57.8M+63.0%	-$156.2M-19.4%	-$130.8M+11.7%	-$148.2M-178.5%	-$53.2M
Capital Expenditures	$13.2M-0.1%	$13.3M-16.3%	$15.8M+2.6%	$15.4M+135.0%	$6.6M+269.8%	$1.8M
Free Cash Flow	-$119.0M-67.5%	-$71.0M+58.7%	-$172.0M-17.6%	-$146.2M+5.5%	-$154.7M-181.4%	-$55.0M
Investing Cash Flow	$88.6M-36.7%	$139.9M+417.8%	-$44.0M+90.1%	-$444.4M-391.0%	-$90.5M-510.2%	$22.1M
Financing Cash Flow	-$3.0M-15.9%	-$2.6M+98.7%	-$193.1M-788.4%	$28.1M-97.6%	$1.2B+4588.6%	$24.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0-100.0%	$200.0M	$0	$0-100.0%	$6.7M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$23.7M+215.5%	-$20.5M-13.1%	-$18.2M+48.3%	-$35.1M-9.7%	-$32.0M-294.8%	$16.4M+313.2%	-$7.7M+58.8%	-$18.7M
Capital Expenditures	$3.1M+4.5%	$3.0M-6.5%	$3.2M-2.3%	$3.3M-15.6%	$3.8M+17.9%	$3.3M-7.6%	$3.5M+6.7%	$3.3M
Free Cash Flow	$20.6M+187.8%	-$23.5M-10.2%	-$21.3M+44.4%	-$38.3M-7.0%	-$35.8M-372.5%	$13.2M+217.1%	-$11.2M+49.0%	-$22.0M
Investing Cash Flow	$19.3M-14.7%	$22.6M+21.0%	$18.7M-73.5%	$70.5M+405.2%	-$23.1M-197.5%	$23.7M-49.2%	$46.6M+155.6%	$18.2M
Financing Cash Flow	-$5.1M-30176.5%	-$17K+92.8%	-$236K+90.9%	-$2.6M-1502.5%	-$161K-631.8%	-$22K+98.4%	-$1.4M+18.0%	-$1.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$0	$0	N/A

AGL Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-7.8%-3.0pp	-4.8%+0.6pp	-5.4%-1.0pp	-4.4%+20.1pp	-24.5%-19.8pp	-4.7%
Net Margin	-6.6%-2.3pp	-4.3%+1.8pp	-6.1%-1.6pp	-4.5%+22.3pp	-26.7%-21.8pp	-4.9%
Return on Equity	-308.8%-253.5pp	-55.2%-15.6pp	-39.7%-29.4pp	-10.2%+27.0pp	-37.2%	N/A
Return on Assets	-30.8%-15.8pp	-15.0%+0.1pp	-15.1%-8.8pp	-6.3%+19.3pp	-25.6%-12.2pp	-13.5%
Current Ratio	1.02-0.2	1.27-0.2	1.51-1.2	2.71-1.1	3.83+2.7	1.10
Debt-to-Equity	0.12+0.1	0.07+0.0	0.05+0.0	0.040.0	0.04+0.3	-0.23
FCF Margin	-2.0%-0.8pp	-1.2%+2.8pp	-4.0%+2.1pp	-6.1%+4.0pp	-10.2%-5.7pp	-4.5%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	0.3%+12.6pp	-12.3%-3.2pp	-9.2%-0.8pp	-8.3%-6.9pp	-1.4%+5.7pp	-7.1%+2.1pp	-9.2%-6.3pp	-2.9%
Net Margin	3.4%+15.5pp	-12.0%-4.4pp	-7.7%-0.2pp	-7.5%-8.3pp	0.8%+7.7pp	-7.0%+1.2pp	-8.1%-6.0pp	-2.1%
Return on Equity	27.0%+176.0pp	-149.0%-113.0pp	-36.0%-10.5pp	-25.5%-27.9pp	2.4%+24.9pp	-22.5%-2.0pp	-20.5%-15.9pp	-4.5%
Return on Assets	3.3%+18.1pp	-14.9%-8.0pp	-6.9%-0.8pp	-6.1%-6.7pp	0.6%+6.7pp	-6.1%-0.5pp	-5.6%-4.2pp	-1.4%
Current Ratio	1.04+0.0	1.02-0.1	1.08-0.1	1.16-0.0	1.20-0.1	1.27-0.0	1.29-0.1	1.36
Debt-to-Equity	0.08-0.0	0.12+0.1	0.000.0	0.000.0	0.00-0.1	0.07+0.0	0.06+0.0	0.04
FCF Margin	1.5%+2.9pp	-1.5%0.0pp	-1.5%+1.3pp	-2.8%-0.4pp	-2.3%-3.2pp	0.9%+1.6pp	-0.8%+0.7pp	-1.5%

Similar Companies

Nutex Health Inc NUTX

$1.3B

AUNA S.A. AUNA

$382.9M

Community Health Sys Inc CYH

$521.4M

Enhabit EHAB

$706.9M

Sonida Senior Living Inc SNDA

$1.9B

Frequently Asked Questions

What is Agilon Health Inc's annual revenue?

Agilon Health Inc (AGL) reported $5.9B in total revenue for fiscal year 2025. This represents a -2.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Agilon Health Inc's revenue growing?

Agilon Health Inc (AGL) revenue declined by 2.1% year-over-year, from $6.1B to $5.9B in fiscal year 2025.

Is Agilon Health Inc profitable?

No, Agilon Health Inc (AGL) reported a net income of -$391.3M in fiscal year 2025, with a net profit margin of -6.6%.

What is Agilon Health Inc's EBITDA?

Agilon Health Inc (AGL) had EBITDA of -$434.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Agilon Health Inc have?

As of fiscal year 2025, Agilon Health Inc (AGL) had $173.7M in cash and equivalents against $15.8M in long-term debt.

What is Agilon Health Inc's operating margin?

Agilon Health Inc (AGL) had an operating margin of -7.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Agilon Health Inc's net profit margin?

Agilon Health Inc (AGL) had a net profit margin of -6.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Agilon Health Inc's return on equity (ROE)?

Agilon Health Inc (AGL) has a return on equity of -308.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Agilon Health Inc's free cash flow?

Agilon Health Inc (AGL) generated -$119.0M in free cash flow during fiscal year 2025. This represents a -67.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Agilon Health Inc's operating cash flow?

Agilon Health Inc (AGL) generated -$105.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Agilon Health Inc's total assets?

Agilon Health Inc (AGL) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Agilon Health Inc's capital expenditures?

Agilon Health Inc (AGL) invested $13.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Agilon Health Inc have outstanding?

Agilon Health Inc (AGL) had 17M shares outstanding as of fiscal year 2025.

What is Agilon Health Inc's current ratio?

Agilon Health Inc (AGL) had a current ratio of 1.02 as of fiscal year 2025, which is considered adequate.

What is Agilon Health Inc's debt-to-equity ratio?

Agilon Health Inc (AGL) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Agilon Health Inc's return on assets (ROA)?

Agilon Health Inc (AGL) had a return on assets of -30.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Agilon Health Inc's cash runway?

Based on fiscal year 2025 data, Agilon Health Inc (AGL) had $173.7M in cash against an annual operating cash burn of $105.8M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Agilon Health Inc's Altman Z-Score?

Agilon Health Inc (AGL) has an Altman Z-Score of 2.32, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Agilon Health Inc's Piotroski F-Score?

Agilon Health Inc (AGL) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Agilon Health Inc's earnings high quality?

Agilon Health Inc (AGL) has an earnings quality ratio of 0.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Agilon Health Inc cover its interest payments?

Agilon Health Inc (AGL) has an interest coverage ratio of -69.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Agilon Health Inc?

Agilon Health Inc (AGL) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.